PURPOSE: The purpose of this study was to evaluate the prognostic role of interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α) in the survival of patients with advanced cancer. METHODS: In this prospective cohort study between three hospice and palliative care centres in South Korea, we followed 98 advanced cancer patients until death or the end of the study. Approximately 60 % of the patients had poor functional status (Eastern Cooperative Oncology Group score ≥3). We investigated the symptoms of cancer cachexia anorexia syndrome, possible cytokine-related confounders such as infection and medication records. Influence from clinical variables was adjusted using the Cox proportional hazard model. RESULTS: The median survival time was 27 days. On multivariate analysis, elevated IL-6 (hazard ratio, 2.139; p = 0.003) was found to be an independent significant prognostic factor. TNF-α was not a significant factor. Poor performance status and male gender were also independently related to shortened survival. CONCLUSIONS: IL-6 level can be a useful indicator of survival time of patients with advanced cancer at the very end of life. In contrast, the prognostic role of TNF-α requires further study.
PURPOSE: The purpose of this study was to evaluate the prognostic role of interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α) in the survival of patients with advanced cancer. METHODS: In this prospective cohort study between three hospice and palliative care centres in South Korea, we followed 98 advanced cancerpatients until death or the end of the study. Approximately 60 % of the patients had poor functional status (Eastern Cooperative Oncology Group score ≥3). We investigated the symptoms of cancer cachexia anorexia syndrome, possible cytokine-related confounders such as infection and medication records. Influence from clinical variables was adjusted using the Cox proportional hazard model. RESULTS: The median survival time was 27 days. On multivariate analysis, elevated IL-6 (hazard ratio, 2.139; p = 0.003) was found to be an independent significant prognostic factor. TNF-α was not a significant factor. Poor performance status and male gender were also independently related to shortened survival. CONCLUSIONS:IL-6 level can be a useful indicator of survival time of patients with advanced cancer at the very end of life. In contrast, the prognostic role of TNF-α requires further study.
Authors: Sang Mi Kwak; Youn Seon Choi; Ho Min Yoon; Dae Gyun Kim; Seung Hun Song; Young Jae Lee; Chang Hwan Yeom; Su Jin Koh; Jeanno Park; Myung Ah Lee; Sang-Yeon Suh Journal: Palliat Med Date: 2011-08-01 Impact factor: 4.762
Authors: Young Ho Yun; Xin Shelley Wang; Jung Suk Lee; Ju Won Roh; Chang Geol Lee; Won Sup Lee; Keun Seok Lee; Soo-Mee Bang; Tito R Mendoza; Charles S Cleeland Journal: J Pain Symptom Manage Date: 2005-02 Impact factor: 3.612
Authors: Chin Hao Chang; Chin Fu Hsiao; Yu Min Yeh; Gee Chen Chang; Ying Huang Tsai; Yuh Min Chen; Ming Shyan Huang; Hui Ling Chen; Yao Jen Li; Pan Chyr Yang; Chien Jen Chen; Chao A Hsiung; Wu Chou Su Journal: Int J Cancer Date: 2012-10-29 Impact factor: 7.396
Authors: Sanjay Rao; Elias George Kikano; Daniel Arnold Smith; Ezgi Guler; Sree Harsha Tirumani; Nikhil H Ramaiya Journal: Abdom Radiol (NY) Date: 2021-01-01
Authors: Kimbell L Hetzler; Justin P Hardee; Melissa J Puppa; Aditi A Narsale; Shuichi Sato; J Mark Davis; James A Carson Journal: Biochim Biophys Acta Date: 2014-12-30
Authors: Nelson Inácio Pinto; June Carnier; Lila M Oyama; Jose Pinhata Otoch; Paulo Sergio Alcântara; Flavio Tokeshi; Claudia M Nascimento Journal: Mediators Inflamm Date: 2015-10-05 Impact factor: 4.711